Daiichi's Pexidartinib Likely Needs REMS For Liver Safety Concerns

 
• By Derrick Gingery
  
Cancer cells on scientific background.3d illustration
Daiichi Sankyo's pexidartinib showed a statistically significant improvement in overall response rate in TCGT patients compared to placebo. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers